Supplementary Figure and Figure Legends from CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

This file contains the supplementary figures and figure legends. Figure S1: CHK1 overexpression and LY2606368 targeting efficacy in SCLC. Figure S2:Combinatorial effect of LY2606368 and cisplatin. Figure S3: Anti-tumor efficacy of LY2606368. Figure S4: Effect of LY2606368 in platinum-resistant SCLC models. Figure S5: Combinatorial effect of LY2606368 and olaparib. Figure S6 and S7: Proteomic biomarkers of LY2606368 response. Figure S8: MYC expression predicts sensitivity to LY2606368.